Specifications

Small molecule-induced protein degradation is an attractive strategy for the development of chemical probes. Protein degraders have the power to abrogate all of the functions of a drug target at once, including scaffolding functions which are difficult to target with small molecule inhibitors. A novel class of PROTACs that incorporate small molecule VHL ligands to successfully degrade HaloTag7 fusion proteins is developed. HaloPROTACs will inspire the development of future PROTACs with more drug-like properties. In HEK 293 cells stably expressing GFP-HaloTag7, 24 hour treatment with HaloPROTAC1 leads to less than 20% degradation, the longer HaloPROTAC2 leads to nearly 70% degradation of GFP-Halotag7 at 2.5 μM. HaloPROTACs containing protein degrader 1 leads to nearly 70% degradation of GFP-HaloTag7, when sufficiently long linkers are used. Derivative of the von Hippel-Lindau (VHL) ligand, VH 032, commonly used as a precursor to PROTACs that hijack VHL as the E3 ubiquitin ligase component. Supplied with a primary amine functional handle at a position known not to significantly affect binding to VHL, for ready conjugation to a linker/target protein ligand.

Product Information:

Purity:                                   >98%MW:                                       467.02Formula:                               C22H31ClN4O3SCAS No.                                 1448189-80-7Physical State:                      Lyophilized white powderQuantity:                              5 mg; 10 mg; 25 mgSolubility:                             40 mg/mL in DMSOStorage:                                Store desiccated as supplied at -20°C for up to 3 years. Store solutions at -80°C for up to 6 months or -20°C for up to 1 month.

References

1. Buckley DL et al. HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins. ACS Chem Biol. 2015 Aug 21;10(8):1831-7.2. Zengerle et al (2015) Selective small molecule induced degradation of the BET bromodomain protein BRD4. ACS Chem.Biol. 10 1770 PMID: 260356253. Galdeano et al (2014) Structure-guided design and optimization of small molecules targeting the protein-protein interaction between the von Hippel-Lindau (VHL) E3 ubiquitin ligase and the hypoxia inducible factor (HIF) alpha subunit with in vitro nanomolar affinities. J.Med.Chem. 57 8657

Lifesensors 是一家生物技术公司，致力于为治疗，药物发现和研究市场开发支持技术。通过提供创新的研究工具，确立了在泛素和类泛素蛋白途径中的先进地位。此外，我们的原核和真核蛋白表达平台 SUMOpro 和 SUMOstar 在世界范围内被学术、政府、制药和生物技术实体所使用